Latest News

Cyclophosphamide and rituximab with bortezomib demonstrated high efficacy and tolerability among patients with treatment-naive Waldenström macroglobulinemia, according to a phase 2 trial.

According to a long-term updated analysis, 3 years of bortezomib, lenalidomide, and dexamethasone maintenance did not improve outcomes for patients with high-risk multiple myeloma defined by gene expression profiling.

According to results from the phase 3 RUBY trial, dostarlimab plus carboplatin and paclitaxel followed by dostarlimab and niraparib significantly improved PFS among patients with primary advanced or recurrent endometrial cancer.

A phase 3 study found treatment with APL-1702 had long-term efficacy and safety among patients with cervical histologic high-grade squamous intraepithelial lesions.

According to results from the phase 2 NRG-GY014 trial, tazemetostat failed to show efficacy among patients with endometrioid endometrial carcinoma or ovarian clear cell carcinoma without ARID1A mutations. However, there was potential noted...

The FDA granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least 2 prior lines of therapy, including a BTK...

The FDA has approved mirvetuximab soravtansine for previously treated patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, as detected by an FDA-approved test.

According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.

According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...

According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.